SPOTLIGHT: Replydine halts Phase III to conserve cash


Replidyne has stopped enrollment in its Phase III trial of faropenem, a chronic bronchitis treatment. The company said the move is designed to "conserve its cash assets and support initiatives that include pursuing strategic transactions and maintaining its research programs." Replydine's release